Clinical Trials in Huai'an, Jiangsu
31 recruiting
Showing 1–20 of 31 trials
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled241 locationsNCT06629779
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled300 locationsNCT07028853
Recruiting
Phase 2
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd300 enrolled28 locationsNCT05686642
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Primary Sjogrens Disease
argenx580 enrolled304 locationsNCT06684847
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
Crohn DiseaseStricture; BowelIntestinal Stricture
Second Affiliated Hospital, School of Medicine, Zhejiang University239 enrolled8 locationsNCT05387031
Recruiting
Phase 2Phase 3
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.254 enrolled24 locationsNCT06783114
Recruiting
Not Applicable
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
Stroke, IschemicStroke, Acute
Xinqiao Hospital of Chongqing1,846 enrolled8 locationsNCT05230914
Recruiting
Phase 3
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Graft-Versus-Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.182 enrolled41 locationsNCT06682169
Recruiting
Phase 2
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Gout FlareAcute Gouty ArthritisGout Flares+1 more
Atom Therapeutics Co., Ltd380 enrolled38 locationsNCT07145229
Recruiting
Phase 4
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Cardiac dysfunctionCoronary Heart Disease
SPH Qingdao Growful Pharmacetical Co.,Ltd2,708 enrolled96 locationsNCT07110415
Recruiting
Phase 3
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.420 enrolled50 locationsNCT07251309
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 4
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
Mild stroke
Second Affiliated Hospital of Soochow University580 enrolled18 locationsNCT07095790
Recruiting
Phase 3
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Ischemic Stroke, Acute
Beijing Tiantan Hospital1,380 enrolled82 locationsNCT06157502
Recruiting
Not Applicable
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China404 enrolled15 locationsNCT06051513